The most common primary tumors were melanoma [157 of 373 (42%)] and NSCLC [92 of 373 (25%)], and anti PD-1 drug was the most frequently associated with this cirAE since nivolumab was implicated in 45% of cases (169 of 373) and pembrolizumab in 40% (148 of 373). The gene discussed is PDCD1; the disease is melanoma.